Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.

Profeta, Victoria; McIntyre, Kellie; Wells, McKenzie; Park, Courtney; Lynch, David R

Profeta, Victoria; McIntyre, Kellie; Wells, McKenzie; Park, Courtney; Lynch, David R.

Affiliation

Profeta V; Departments of Pediatrics and Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
McIntyre K; Departments of Pediatrics and Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Wells M; Departments of Pediatrics and Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Park C; Departments of Pediatrics and Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lynch DR; Departments of Pediatrics and Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Expert Opin Investig Drugs ; 32(1): 5-16, 2023 Jan.

Article in En | MEDLINE | ID: mdl-36708320

Subject(s)
Key words

KEAP1; Nrf2 activator; antioxidant response element

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triterpenes / Friedreich Ataxia Limits: Humans Country/Region as subject: America do norte Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google